Sydney skin cancer patients join the EPIC-Skin study as they undergo first treatments with OncoBeta's Rhenium-SCT
By: OncoBeta GmbH
These patients were treated on 8 April and are now part of 210 adults participating in the international study that will follow their progress over the next 24 months.
The EPIC-Skin study is being conducted through study centres located in Australia, Austria, Germany and the United Kingdom. Hosting multiple study centres in Australia, these Sydney patients follow the Gold Coast patients that were the first-globally to be treated as part of the study.
Dr Sam Vohra, Medical Director at OncoBeta Australia, says, "Rhenium-SCT can be applied directly to an affected area, without harming or scarring surrounding tissue. It is important we collect data through the EPIC-Skin Study to further validate the efficacy, safety and patient quality of life after treatment of NMSCs with Rhenium-SCT."
There are more than 7.7 million cases of NMSC each year, and incidence rates are increasing globally.1,2 Standard treatments for NMSCs are surgery-based approaches, which may have a risk of scarring or loss of function. Rhenium-SCT uses a paste containing ß-emitting particles that is applied directly to the lesion, which eliminate cancer cells in one single session† and without the need for surgery.3-5
The EPIC-Skin study will measure Patient Reported Outcomes such as quality of life, treatment comfort and cosmetic outcomes, as well as further evaluating the efficacy of Rhenium-SCT for the treatment of NMSC. To provide a simple and streamlined way to record their experiences, patients in the study will utilise OncoBeta's Clinical Study app.
OncoBeta Australia Country Manager Ken Rikard-Bell says, "NMSC is a significant health concern both here in Australia and around the world. This study will offer new insights into the treatment of NMSC and the role of Rhenium-SCT®
Shannon D. Brown III, CEO and Managing Director at OncoBeta, says, "OncoBeta's goal is to provide the best innovative solutions for patients suffering from NMSCs. The patient journey is sometimes a difficult one and as a healthcare service provider we are committed to making this journey as easy, effective and efficient as possible. The EPIC-Skin Study will be critical in assisting us in improving patient outcomes for those suffering from NMSCs."
About the Rhenium-SCT®
Non-melanoma skin cancer (NMSC) is the most common form of cancer in humans.2 The most common cause of NMSC is sun exposure, while other predisposing factors include genetic skin conditions and immunosuppressive diseases or treatments.6
OncoBeta®, with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-
Find out more about the Rhenium-SCT®
Follow us on social media:
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control, and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
*No reported pain3,4
†Complete tumour regression in 98.5% of lesions treated, with 89% after a single application5